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Pilocytic astrocytoma is commonly viewed as a benign
lesion. However, disease onset is most prevalent in the
ﬁrst two decades of life, and children are often left
with residual or recurrent disease and signiﬁcant mor-
bidity. The Hedgehog (Hh) pathway regulates the
growth of higher WHO grade gliomas, and in this
study, we have evaluated the activation and operational
status of this regulatory pathway in pilocytic astrocyto-
mas. Expression levels of the Hh pathway transcrip-
tional target PTCH were elevated in 45% of tumor
specimens analyzed (ages 1–22 years) and correlated
inversely with patient age. Evaluation of a tissue array
revealed oligodendroglioma-like features, pilomyxoid
features, inﬁltration, and necrosis more commonly in
specimens from younger patients (below the median
patient age of 10 years). Immunohistochemical staining
for the Hh pathway components PTCH and GLI1 and
the proliferation marker Ki67 demonstrated that
patients diagnosed before the age of 10 had higher stain-
ing indices than those diagnosed after the age of 10. A
signiﬁcant correlation between Ki67 and PTCH and
GLI1 staining indices was measured, and 86% of
Ki67-positive cells also expressed PTCH. The oper-
ational status of the Hh pathway was conﬁrmed in
primary cell culture and could be modulated in a
manner consistent with a ligand-dependent mechanism.
Taken together, these ﬁndings suggest that Hh pathway
activation is common in pediatric pilocytic astrocytomas
and may be associated with youngerage atdiagnosis and
tumor growth.
Keywords: Hedgehog, pediatric brain tumor, pilocytic
astrocytoma.
P
ilocytic astrocytoma is the most common pediatric
brain tumor and commonly viewed as a benign
lesion with excellent prognosis.
1–4 Estimated
10-year survival rates range from 90% to 96.8%.
3,5
However, the 20-year survival and progression-free sur-
vival rates of approximately 70% and 40%, respect-
ively,
6–8 reﬂect the indolent nature of this disease.
Furthermore, survivors of pilocytic astrocytomas com-
monly suffer long-term sequelae related to disease and
treatment.
9–13 Thus, a better understanding of pilocytic
astrocytoma biology is needed to guide the development
of new therapies to decrease morbidity and improve
survival.
Hedgehog (Hh) signaling is one mechanism impli-
cated in the growth of two other types of primary brain
tumors, medulloblastoma and malignant glioma.
14,15
Additionally, recent limited clinical data indicate that
targeted inhibition of the Hh pathway may be thera-
peutically beneﬁcial for certain patients with medullo-
blastoma.
16 In a prior survey of WHO grade I–IV
glioma specimens that included a small collection of
pilocytic astrocytomas from adult patients, protein and
transcript expression proﬁles for the Hh receptor
Patched (PTCH) suggested that the Hh pathway might
be activated to a small extent in this astrocytoma
entity.
17 Therefore, in this study, we have investigated
the Hh pathway in a larger panel of pilocytic
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Advance Access publication March 11, 2010astrocytoma specimens from pediatric patients. We
demonstrate that the Hh pathway is operational in
sporadic pilocytic astrocytomas and activated to a
greater extent in tumors from younger patients.
Furthermore, expression of the Hh pathway signal trans-
duction components correlates with expression of the
cellular proliferation marker Ki67.
Materials and Methods
Tissue Procurement
Brain tumor and epilepsy specimens from patients
treated at the Vanderbilt Medical Center from 2003
to 2008 were obtained in accordance with the
Institutional Review Board’s approval. Primary brain
tumors were phenotyped and graded using the World
Health Organization criteria,
18,19 and 20 specimens
classiﬁed as pilocytic astrocytoma were used for these
studies (Table 1). Pilocytic astrocytoma patient ages
ranged from 1 to 22 years, and patients with a diagnosis
of neuroﬁbromatosis type 1 and pilomyxoid astrocy-
toma were not included. The epilepsy control specimens
were obtained from patients who were 37–57 years old.
The locations of the pilocytic astrocytomas varied: 14 in
the cerebellum, 2 in the midbrain,1 in the temporallobe,
1 in the frontal lobe, 1 in the thalamus, and 1 in the
suprasellar region (Table 1). RNA was extracted for
quantitative real-time PCR (qRT-PCR) studies from 18
of the tumor specimens for which excess tissue was avail-
able for banking in a research tissue repository. Tissue
cores were removed for tissue microarray construction
from 17 of the tumor specimens that contained sufﬁcient
material in parafﬁn blocks. Primary cell cultures were
generated from 4 of the tumor specimens for which ade-
quate excess tissue was available.
RNA Extraction, cDNA Synthesis, and qRT-PCR
Total RNA was extracted from brain tissue or primary
cell cultures with the RNeasy Mini Kit (QIAGEN).
Genomic DNA was removed (RNase-Free DNase
Set, QIAGEN) and puriﬁed RNA was quantiﬁed
(RiboGreen RNA Quantitation Kit, Molecular Probes).
Single-stranded cDNA was synthesized with oligo(dT)
and random hexamer primers (iScript cDNA Synthesis
Kit, Bio-Rad). For negative controls, reverse transcrip-
tase was omitted from the synthesis reaction (2RT).
For all measurements, qRT-PCR was performed in tri-
plicate for each sample and on the corresponding 2RT
control.Forprimarybraintumorandepilepsyspecimens,
qRT-PCR reactions were performed with SYBR Green
Supermix (Bio-Rad), cDNA template, and 200 nM
primersforPTCHandglyceraldehyde3-phosphatedehy-
drogenase (GAPDH).
17 Additionally, measurements in
primary brain tumors were corroborated using the
TaqMan primers for PTCH (Hs00970979_m1) and
GAPDH (Hs99999905_m1). For primary cell cultures,
qRT-PCR reactions were performed with the TaqMan
Table 1. Clinical and pathological features and the molecular analyses of pilocytic astrocytomas










1 1.8 P Cerebellum Pilomyxoid features 2.30 9.01 0.29 0.15
2 2.1 P Cerebellum Inﬁltration and oligodendroglioma-like 5.72 4.67 0.79 0.35
3 2.5 P Cerebellum Inﬁltration/pilomyxoid features 11.5 15.15 6.90 0.10
4 2.6 P Cerebellum Classic architecture 3.56 6.29 2.38 1.08
5 3.4 P Cerebellum Inﬁltration 10.6 12.85 1.41 0.12
6 4.1 P Suprasellar Pilomyxoid features and necrosis 1.25 32.17 13.91 0.55
7 4.7 P Midbrain, exophytic Pilomyxoid features NA 6.54 2.73 0.06
8 4.7 P Cerebellum Inﬁltration 5.01 28.26 19.68 0.93
9 5.3 R Midbrain, exophytic Pilomyxoid and oligodendroglioma-like features 7.42 24.05 18.18 1.85
10 6.7 P Cerebellum and
midbrain
Pilomyxoid features and increased proliferation 1.72 36.57 27.20 2.77
11 13.7 P Cerebellum Classic architecture 1.93 6.81 0.00 0.00
12 14 R Cerebellum Classic architecture NA 4.90 0.37 0.18
13 14.3 P Cerebellum Oligodendroglioma-like features 3.80 NA NA NA
14 14.8 P Cerebellum Classic architecture 0.67 13.39 4.17 0.06
15 16.7 P Temporal lobe Classic architecture 1.03 NA NA NA
16 18.3 P Cerebellum Classic architecture 3.81 NA NA NA
17 18.8 P Cerebellum Classic architecture 0.820 NA NA NA
18 20.1 P Frontal lobe Classic architecture 1.23 9.70 0.74 0.03
19 21 R Cerebellum and
suprasellar
Classic architecture 1.41 NA NA NA
20 22 P Thalamus Classic architecture 1.86 3.49 2.68 0.09
Abbreviations: P, primary tumor; R, recurrent tumor; PTCH, patched; IHC, immunohistochemistry; Ki67-LE, Ki67 labeling index.
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cDNA template, and primers (TaqMan Gene
Expression Assay, Applied Biosystems) for hPTCH
(Hs00970979_m1), hGLI1 (Hs00171790_m1), and
hGAPDH (Hs99999905_m1), respectively.
15 For stan-
dardcurves, qRT-PCR wasperformed on serial dilutions
of a human cDNA mixture.
17 For each amplicon, quan-
tities were determined according to the standard curve
method (User Bulletin #2, PE Applied Biosystems).
Tissue Microarray Construction
and Immunohistochemical Analysis
Surgical pathology slides were reviewed (by T.W.A.) to
identify tumor regions of interest and any normal
brain structures. The slides were marked and delivered
to the Vanderbilt Human Tissue Acquisition and
Pathology Core to identify the corresponding regions
on the formalin-ﬁxed, parafﬁn-embedded donor blocks
and construct a tissue microarray. Four tissue cores
(1.0 mm diameter) were removed from each donor
block, assigned a coded identiﬁer, and manually placed
in nonadjacent positions of the recipient microarray
block. Twenty consecutive sections (5 mm) from the
tissue microarray were mounted on silanized slides.
Sections 1 and 20 were stained with hematoxylin and
eosin to conﬁrm sample integrity, and sections 2–19
were used for the immunohistochemical analysis.
Immunohistochemistry was performed with the
following antibodies: PTCH-1 (1:100; Santa Cruz
Biotechnologies), Ki67 (1:50; DAKO), Bmi-1 (1:100;
Upstate), and Gli-1 (1:50; Cell Signaling). The slides
were deparafﬁnized and microwaved in a citrate buffer
(pH 6.0) for antigen retrieval. They were treated with
3% hydrogen peroxide solution, incubated in blocking
serum, and incubated in primary antibody overnight at
48C. Biotinylated secondary antibody was incubated
overnight at 48C, and immunodetection with 3,3′-
diaminobenzidine or 5-bromo-4-chloro-3-indolyl
phosphate/nitro blue tetrazolium (BCIP/NBT) substrate
was performed using the Vectastain Elite ABC kit
(Vector Laboratories).
Staining indices for each sample on the microarray
were determined by dividing the average number of
cells that stained positively for PTCH, GLI1, or Ki67
per high-power microscopic ﬁelds (hpf) by the total
number of cells per hpf. Cells staining for PTCH,
GLI1, and Ki67 were counted in 9 hpf for each sample
on the single-antibody–labeled slides. The total
numbers of cells were counted in 4 hpf for each sample
on a slide stained with hematoxylin. Depending on
tissue integrity, values for each tumor were obtained
from at least 2 samples on every microarray slide.
Tumor identity was determined only after the staining
was scored.
Cell Culture and Hh Signaling Assays
Tumor samples were dissociated (Papain, Worthington
Biochemical Corporation) and plated in DMEM/F12,
10% FBS, and 1× penicillin–streptomycin (Invitrogen).
After primary cell cultures reached conﬂuency, they
were plated for 7 days in nontreated polystyrene ﬂasks
(BD-Falcon) in NeuroCult medium with supplements
(NeuroCult NS-A Proliferation Kit; Stem Cell
Technologies), 2 mg/mL heparin (Sigma), 20 ng/mL
EGF (ProSpec-Tany TechnoGene), 10 ng/mL bFGF
(ProSpec-Tany TechnoGene), and 1× penicillin-
streptomycin (Invitrogen). The resulting spheres of cells
were transferred to nontreated polystyrene multiwell
plates (BD-Falcon) and cultured in triplicate for
40 hours either alone, with 50 nM smoothened agonist
(SAG), with 500 nM SAG, or with 200 nM smoothened
antagonist(SANT1).ForassaysofHhpathwayinhibition,
conﬂuent cultures were plated in nontreated polystyrene
ﬂasks (BD-Falcon) in NeuroCult medium with sup-
plements (NeuroCult NS-A Proliferation Kit; Stem Cell
Technologies), 2 mg/mL heparin (Sigma), 1× penicillin–
streptomycin(Invitrogen),and50 nMSAG.Theresulting
spheres of cells were transferred to multiwell plates and
cultured in triplicate for 48 hours either with 50 nM
SAG or with 200 nM SANT1. GLI1 and GAPDH levels
were measured by qRT-PCR as described above.
Statistical Analysis
To measure the correlation between two variables, the
Pearson product–moment correlation coefﬁcient was
calculated with a 99% conﬁdence interval (GraphPad
Prism). Student’s t-test was used to compare the mean
values from the 2 groups.
Results
PTCH mRNA Expression Levels in Pilocytic
Astrocytomas Correlate Inversely with Age
To evaluate the Hh pathway activity, PTCH mRNA
levels were measured by qRT-PCR in 18 of the pilo-
cytic astrocytomas evaluated in this study (Table 1)
and in 3 specimens from patients with epilepsy
(Fig. 1). PTCH is a signal transduction component
and direct gene target of Hh signaling, whose
expression level can serve as a metric for pathway
activity.
20,21 For all samples, PTCH levels were nor-
malized to endogenous GAPDH levels and expressed
as the fold difference relative to control samples
resected from patients with epilepsy. Compared with
control specimens, PTCH RNA expression was elev-
ated in 45% of the pilocytic astrocytoma specimens
(Fig. 1). A signiﬁcant inverse correlation between
PTCH expression levels and patient age (Pearson’s
test, r ¼ 2.59, P ¼ .0097) suggests that the Hh
pathway may be activated in pilocytic astrocytomas
from younger patients. When grouped according to
diagnosis before and after the median patient age of
10, median PTCH levels were 5.01 and 1.23, respect-
ively (Student’s t-test, P ¼ .013; Fig. 2A).
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Astrocytomas Correlate with that of a Cellular Marker
for Proliferation
To corroborate these ﬁndings, pathological features of
the 20 pilocytic astrocytoma specimens (Table 1) were
reviewed for tissue microarray construction. Compact
growth patterns and biphasic architectural organiz-
ational patterns predominated in all specimens.
However, 9 of the patient samples demonstrated at
least one additional histological feature that included
oligodendroglioma-like qualities, pilomyxoid features,
leptomeningeal spread, focal areas of increased prolifer-
ation,necrosis, orfocal inﬁltrativegrowth (Fig. 3).These
pathological features were more prevalent in patients
diagnosed with pilocytic astrocytoma before the age of
10 (Table 1), and several have been associated with
poorer outcome.
4,22–24 Four tissue cores from 17 of
the donor parafﬁn blocks that contained sufﬁcient
material were included in a recipient microarray block.
Immunohistochemistry was performed for the Hh recep-
tor PTCH and the Hh transcription factor GLI1, and
staining was scored in an investigator-blinded fashion.
Adequate tissue for the immunohistochemical analysis
was available for 15 of the 17 tumors on the tissue
microarray sections.
Single-label staining for PTCH or GLI1 produced
concordant results for each donor tissue core, with
greater numbers of cells labeled for PTCH than GLI1
in all instances (Fig. 4 and Supplementary Material,
Fig. S1). A notable feature of this type of analysis was
variability in PTCH or GLI1 staining indices among
some of the tissue cores sampled from the same tumor
(Supplementary Material, Table S1 and Fig. S2). This
suggests that pilocytic astrocytomas are heterogeneous
with respect to Hh pathway component expression.
Consistent with this interpretation, the PTCH or GLI1
staining indices from one portion of a tumor did not
always correspond with the PTCH mRNA expression
level measured in another portion of the same tumor
(Table 1). However, as for PTCH mRNA measurements,
higher staining indices for PTCH and GLI1 were
measured in tumors from younger patients (Fig. 2). In
specimens from patients diagnosed before and after the
Fig. 2. Comparison of age at diagnosis and molecular analyses of Hedgehog pathway activation. (A) When grouped according to diagnosis
before and after the age of 10 years, median PTCH levels are 5.01 and 1.23, respectively (Student’s t-test, P ¼ .013). (B and C) Higher
staining indices for PTCH and GLI1 are measured in tumors from younger patients. In specimens from patients diagnosed before and
after the age of 10, the median values for PTCH are 14.00 and 6.81, respectively (Student’s t-test, P ¼ .033; B) and for GLI1 they are
4.82 and 0.74 (Student’s t-test, P ¼ .034; C).
Fig. 1. PTCH mRNA expression in pilocytic astrocytomas. Graphic illustration of the relative PTCH expression levels from samples listed in
Table 1 revealed a signiﬁcant inverse correlation with patient age (Pearson’s test, r ¼ 2.59, P ¼ .0097).
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6.81, respectively (Student’s t-test, P ¼ .033; Fig. 2B),
and for GLI1 they were 4.82 and 0.74 (Student’s t-test,
P ¼ .034; Fig. 2C).
Toevaluatecellularproliferation,Ki67immunohisto-
chemistry was performed with the pilocytic astrocytoma
tissue microarray. Consistent with other reports, Ki67
labeling indices ranged from 0% to 2.77% and were
higher in younger patients (Table 1).
25,26 In addition,
a signiﬁcant correlation between Ki67 and PTCH
(Pearson’s test, r ¼ .68, P ¼ .0058) and between Ki67
and GLI1 (Pearson’s test, r ¼ .82, P ¼ .0002) staining
indices was measured. To corroborate these obser-
vations, double-labeling experiments were performed
and revealed that 86% of Ki67-positive cells expressed
PTCH across all tumors (Fig. 4C and data not shown).
Hh Pathway Modulation Can Be Measured in Primary
Cells Cultured from Pilocytic Astrocytomas
In order to assess the operational status of the Hh
pathway, primary cell cultures were generated from 4
pilocytic astrocytomas (sample numbers 6, 10, 15, and
18; Table 1) and 2 higher-grade adult astrocytomas
that served as controls. Under culture conditions that
are required for eliciting an Hh pathway response,
17
the addition of an SAG (50 nM) induced a signiﬁcant
increaseinGLI1mRNAexpression in2ofthe 4pilocytic
astrocytomacultures(samplenumbers6and18;P , .05,
Student’s t-test; Fig. 5A). The basal expression levels of
GLI1 transcript were not reduced by treatment with a
SANT1 (200 nM)
27 in any of the astrocytoma cultures
(Fig. 5A). The levels of GLI1 induction in the pilocytic
Fig. 3. Putative aggressive pathological features in pilocytic astrocytoma specimens. (A–F) Putative aggressive features noted on review of
20 anonymized pilocytic astrocytoma specimens. Tumor inﬁltration demonstrated by entrapped neuronal cell bodies (arrowhead in A) and
axons coursing through the neoplasm (arrowhead in B, neuroﬁlament stain), oligodendroglioma-like features (C), pilomyxoid features
(arrowheads in D), leptomeningeal spread (arrowheads in E), and necrosis (arrowhead in F) were noted in 9 of the patient samples.
These pathological features were more prevalent in patients diagnosed prior to the age of 10 (Table 1). Scale bar indicates 50 mmi n
A and B, 100 mm in C and D, and 500 mm in E and F.
Fig. 4. Hedgehog pathway component expression in a pilocytic astrocytoma specimens. (A–C) Representative image of a pilocytic
astrocytoma from a tissue microarray stained with hematoxylin and eosin (A) and for GLI1 (arrowheads in B), and PTCH and Ki67 (C).
Arrowhead in C demonstrates a PTCH
+/Ki67
+ cells. Scale bar ¼ 50 mm.
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in a Hh-responsive WHO grade II astrocytoma control
culture (Fig. 5A). Consistent with prior studies, GLI1
expression levels were not induced by the SAG treatment
of a primary GBM culture that served as a negative
control in the analysis.
15,17 The ﬁndings from this
survey of 4 tumors provide evidence that the Hh
pathway is operationally intact within a subset of pilocy-
tic astrocytomas.
To conﬁrm the modulatory status of the Hh pathway,
dose-dependentinductionofGLI1mRNAwithSAGwas
assayed (Fig. 5B). To determine whether once activated
the pathwaycould thenbe inhibited, aculturewasgener-
atedinthepresenceofSAG.After7days,aportionofthe
spheres from the parent culture was re-plated in the pres-
ence of SANT1. The GLI1 levels were elevated in the
parent culture derived in the presence of SAG and could
be reduced to basal levels by SANT1 treatment
(Fig. 5C). These data demonstrate that Hh signaling in
a pilocytic astrocytoma primary culture can be modu-
lated by either activation or inhibition, thereby conﬁrm-
ing the operational status of the pathway.
Discussion
A role foraberrant Hhsignalingin tumorigenesiswasﬁrst
appreciated with the discovery that the autosomal domi-
nant disorder, Gorlin’s syndrome, is associated with
mutations in the PTCH gene.
28,29 Patients with Gorlin’s
syndrome (also called basal cell nevus syndrome) display
an increased incidence of basal cell carcinoma and medul-




Fig. 5. Characterization of Hedgehog pathway responsiveness in primary cell cultures from pilocytic astrocytomas. (A) Astrocytic tumors
were grown as spheres under stem cell culture conditions. Cells from a Hh-responsive astrocytoma (GII A), a Hh-unresponsive GBM
(GIV GBM), and 4 pilocytic astrocytomas (GI PA-6, GI PA-10, GI PA-15, and GI PA-18) were cultured for 36 hours either alone
(control), with 50 nM SAG, or with 200 nM SANT1. In triplicate wells for each cell line and culture condition, the GLI1 levels were
normalized to GAPDH and expressed relative to the untreated control cultures. (B) To conﬁrm a dose-dependent response to Hh
pathway stimulation, the GI PA-18 cells were cultured in triplicate wells either alone (control), with 50 nM SAG, or with 200 nM SAG.
After 40 hours, the GLI1 levels were normalized to GAPDH and expressed relative to the untreated control cultures. (C) To determine
whether Hh signaling could be inhibited following pathway activation, the GI PA-18 cells were cultured in the presence of SAG (50 nM)
for 7 days and then re-plated in triplicate wells containing either 50 nM SAG or 200 nM SANT1. After an additional 48 hours in culture,
the GLI1 levels were normalized to GAPDH and expressed relative to the SAG-treated cultures. GI, WHO grade I; GII, WHO grade II;
GIV, WHO grade IV; A, astrocytoma; AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; PA, pilocytic astrocytoma; SAG,
smoothened agonist; SANT, smoothened antagonist; *P ≤.05.
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35 have been identiﬁed in approximately 30% of
sporadic medulloblastoma specimens. Mutations in
these3Hhcomponentsconfer“ligand-independent”acti-
vation of the pathway. In contrast, “ligand-dependent”
activation of the Hh pathway has been identiﬁed in a
broader array of malignancies
36 including a subset of
malignant gliomas.
17,37–39 Here, we show ligand-
dependent activation of the Hh pathway in a subset of
pilocytic astrocytomas, low-grade gliomas that are clini-
cally and genetically distinct from malignant gliomas.
Hh signaling in primary brain tumors and the diver-
gent mechanisms by which the pathway is activated
illustrate several features that are pertinent to the ﬁnd-
ings in this study. First, the incidence of Hh pathway
activation in sporadic medulloblastomas can be deﬁned
with greater precision by mutational analysis. In the
case of gliomas, the proportion of tumors in which the
pathway is activated is less well deﬁned in the absence
of clear thresholds for PTCH and GLI1 expression
levels to deﬁne an “on” or “off” state. Second, in con-
trast to medulloblastomas, in which clonal deregulation
of Hh signaling is driven by mutations in the pathway,
marked cellular heterogeneity in the expression of Hh
pathway components suggests that the Hh pathway is
activated in only a portion of tumor cells in malignancies
with a ligand-dependent mechanism of activation.
Lastly, a requirement for the Hh pathway activity
in the growth of medulloblastomas and malignant
gliomas has been demonstrated in animal transplan-
tation models.
14,15
In these studies, we demonstrate that the Hh pathway
is activated in a subset of pilocytic astrocytomas.
Complementary methods to assess the expression of
the Hh pathway components and gene targets PTCH
and GLI1 were utilized, and multiple regions of the
same tumor were sampled. Pilocytic astrocytomas are
characterized by marked heterogeneity in cytoarchitec-
ture and patterns of cellular organization. With regard
to PTCH and GLI1 expression, we ﬁnd that levels vary
with respect to the portion of tumor sampled.
Signaling assays with primary cell cultures conﬁrm that
the Hh pathway is operational in pilocytic astrocytomas.
The Hh pathway could be modulated in only a subset of
primary cell cultures, consistent with heterogeneity in
either the operational status of the pathway or the
portion of tumor selected for culture. The ability to sig-
niﬁcantly induce GLI1 mRNA with SAG combined with
the inability to inhibit the basal GLI1 levels with an
antagonist suggests that Hh signaling is not constitu-
tively activated.
27,40 Therefore, as in WHO grade II
and III gliomas, the Hh pathway appears to be activated
in a ligand-dependent manner in pilocytic astrocyto-
mas.
15,17 A role for Hh signaling in pilocytic astrocyto-
mas cannot be determined in the absence of animal
models for sporadic disease. However, a notable
feature of our studies is the demonstration of a signiﬁ-
cant correlation between Ki67 and PTCH and GLI1
staining. This ﬁnding suggests that, as for other
primary brain tumor types,
14,15 Hh signaling may regu-
late the growth of pilocytic astrocytomas.
Combined with the prior measurements of low PTCH
expression in adult pilocytic astrocytomas,
17 the inverse
correlation between PTCH mRNA and patient age in
this studysuggeststhatthe Hh pathwaymaybe activated
to a greater extent in younger patients. Although
some studies suggest that younger age at diagnosis
portends shorter progression-free survival,
41,42 this has
not been validated by other series.
1,4,43 Additionally,
we observed that potentially aggressive histological
features were more commonly associated with tumors
from younger patients. In particular, some series
suggest that necrosis, oligodendroglioma-like features,
and inﬁltrative growth are associated with decreased
event-free survival.
4,24 Evaluation of a larger series of
tumor samples will be required to determine if the Hh
pathway is activated to a greater extent in pilocytic
astrocytomas from younger patients and whether this
correlates with speciﬁc histopathologic features and
tumor progression.
Recent ﬁndings implicate aberrant activation of
the MAPK pathway, due to BRAF gene rearrangements
or mutations, in 66%–85% of sporadic pilocytic
astrocytomas.
44–47 Integration of MAPK and Hh signal-
ing, by ERK-mediated control of the GLI function, has
been implicated in the regulation of cellular proliferation
in basal cell and gastric carcinomas.
48–50 Whether the
MAPK and the Hh pathways function synergistically
to regulate the growth of pilocytic astrocytomas war-
rants further study. In this respect, there remains an
important need for animal models of sporadic pilocytic
astrocytomas.
Supplementary Material
Supplementary material is available at Neuro-Oncology
online.
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